The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach (Q35892321)

11 August 2017

1 reference

title

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach (English)

1 reference

11 August 2017

1 reference

2

Roman Rouzier

1 reference

11 August 2017

3

Kadri Altundag

1 reference

11 August 2017

4

Aman U Buzdar

1 reference

11 August 2017

Paolo Morandi

1

1 reference

11 August 2017

Richard L Theriault

series ordinal

5

1 reference

11 August 2017

Gabriel Hortobagyi

series ordinal

6

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

101

1 reference

11 August 2017

issue

7

1 reference

11 August 2017

page(s)

1482-1489

1 reference

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Quality of health care delivered to adults in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Progesterone Receptor Status Significantly Improves Outcome Prediction Over Estrogen Receptor Status Alone for Adjuvant Endocrine Therapy in Two Large Breast Cancer Databases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Screening for osteoporosis in postmenopausal women: recommendations and rationale

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Adjuvant use of anastrozole in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

New stars in the sky of treatment for early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20522

7 January 2021

Identifiers

DOI

10.1002/CNCR.20522

1 reference

11 August 2017

1 reference